MA40721B1 - Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation - Google Patents

Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Info

Publication number
MA40721B1
MA40721B1 MA40721A MA40721A MA40721B1 MA 40721 B1 MA40721 B1 MA 40721B1 MA 40721 A MA40721 A MA 40721A MA 40721 A MA40721 A MA 40721A MA 40721 B1 MA40721 B1 MA 40721B1
Authority
MA
Morocco
Prior art keywords
interleukin
polypeptide
receptor alpha
methods
fusion proteins
Prior art date
Application number
MA40721A
Other languages
English (en)
Other versions
MA40721A (fr
Inventor
Thomas Malek
Original Assignee
The University Of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40721(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The University Of Miami filed Critical The University Of Miami
Publication of MA40721A publication Critical patent/MA40721A/fr
Publication of MA40721B1 publication Critical patent/MA40721B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

L'invention concerne diverses méthodes et compositions pouvant être utilisées pour moduler le système immunitaire. Les compositions comprennent une protéine de fusion comprenant : (a) un premier polypeptide comprenant l'interleukine-2 (IL-2) ou une variante fonctionnelle ou un fragment de celle-ci ; et (b) un second polypeptide, fusionné dans le cadre du premier polypeptide, le second polypeptide comprenant un domaine extracellulaire du récepteur alpha de l'interleukine-2 (IL-2Rα) ou une variante fonctionnelle ou un fragment de celui-ci, et la protéine de fusion ayant une activité IL-2. L'invention concerne diverses méthodes permettant de moduler la réponse immunitaire chez un sujet, comprenant l'administration à un sujet qui en a besoin d'une quantité thérapeutiquement efficace de la protéine de fusion IL-2/IL-2Rα décrite dans la présente invention.
MA40721A 2014-08-06 2015-08-05 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation MA40721B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033726P 2014-08-06 2014-08-06
EP15750560.3A EP3177307B1 (fr) 2014-08-06 2015-08-05 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
PCT/US2015/043792 WO2016022671A1 (fr) 2014-08-06 2015-08-05 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA40721A MA40721A (fr) 2017-06-13
MA40721B1 true MA40721B1 (fr) 2024-08-30

Family

ID=53836871

Family Applications (2)

Application Number Title Priority Date Filing Date
MA40094A MA40094B1 (fr) 2014-08-06 2015-08-04 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
MA40721A MA40721B1 (fr) 2014-08-06 2015-08-05 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA40094A MA40094B1 (fr) 2014-08-06 2015-08-04 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Country Status (32)

Country Link
US (3) US12084483B2 (fr)
EP (2) EP3177307B1 (fr)
JP (3) JP6723982B2 (fr)
KR (1) KR102653758B1 (fr)
CN (2) CN113912737A (fr)
AU (3) AU2015301071C1 (fr)
BR (1) BR112017001940A2 (fr)
CA (1) CA2957273C (fr)
CL (1) CL2017000284A1 (fr)
CO (1) CO2017002166A2 (fr)
DK (1) DK3177307T3 (fr)
EA (2) EA202091342A3 (fr)
ES (1) ES2986097T3 (fr)
FI (1) FI3177307T3 (fr)
HR (1) HRP20241258T1 (fr)
HU (1) HUE068478T2 (fr)
IL (2) IL250007B (fr)
LT (1) LT3177307T (fr)
MA (2) MA40094B1 (fr)
MX (1) MX388977B (fr)
MY (1) MY180831A (fr)
PE (1) PE20170503A1 (fr)
PH (1) PH12017500042A1 (fr)
PT (1) PT3177307T (fr)
RS (1) RS65930B1 (fr)
SA (1) SA517380842B1 (fr)
SG (2) SG11201700706WA (fr)
SI (1) SI3177307T1 (fr)
SM (1) SMT202400414T1 (fr)
TN (1) TN2017000020A1 (fr)
WO (1) WO2016022671A1 (fr)
ZA (1) ZA201700245B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
RS58149B1 (sr) 2014-02-06 2019-02-28 Hoffmann La Roche Fuzioni proteini interleukina-2 i njihova upotreba
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
EP3458485B1 (fr) * 2016-05-19 2021-12-29 The General Hospital Corporation Interleukine-2 liée à son récepteur il-2rbêta, plate-forme pour améliorer l'activité des cellules tueuses naturelles et des lymphocytes t régulateurs
CN110087681A (zh) 2016-09-28 2019-08-02 佐马美国有限公司 结合白细胞介素-2的抗体和其用途
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3746103A4 (fr) * 2017-12-06 2022-03-30 The Board of Trustees of the Leland Stanford Junior University Protéines modifiées pour améliorer la sensibilité d'une cellule à l'il-2
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3768700A1 (fr) * 2018-03-23 2021-01-27 Kite Pharma, Inc. Protéines transmembranaires chimériques et leurs utilisations
KR102824112B1 (ko) * 2018-03-28 2025-06-24 브리스톨-마이어스 스큅 컴퍼니 인터루킨-2/인터루킨-2 수용체 알파 융합 단백질 및 사용 방법
AU2020242254B2 (en) 2019-03-18 2026-03-12 Biontech Cell & Gene Therapies Gmbh Interleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
CA3141327A1 (fr) 2019-05-20 2020-11-26 Pandion Operations, Inc. Immunotolerance ciblee madcam
JP2022533254A (ja) * 2019-05-24 2022-07-21 プロヴィヴァ セラピューティクス （ホン コン） リミテッド Ｉｌ－２組成物およびその使用方法
US11246906B2 (en) * 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
AU2020315282B2 (en) * 2019-07-12 2026-02-12 Proviva Therapeutics (Hong Kong) Limited IL-2 compositions and methods of use thereof
JP7682150B2 (ja) * 2019-07-25 2025-05-23 ザ・ユニバーシティ・オブ・シカゴ プロテアーゼ活性化治療剤を含む組成物および方法
WO2021055568A1 (fr) * 2019-09-19 2021-03-25 Proviva Therapeutics (Hong Kong) Limited Compositions d'il-2 et leurs procédés d'utilisation
EP4045077A1 (fr) * 2019-10-18 2022-08-24 Alkermes Pharma Ireland Limited Agents il-2 immunolodulateurs en combinaison avec des inhibiteurs de point de contrôle immunitaire
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
WO2021168079A1 (fr) 2020-02-21 2021-08-26 Pandion Operations, Inc. Immunotolérance ciblée sur un tissu avec un effecteur cd39
WO2021222762A2 (fr) 2020-04-30 2021-11-04 Aetio Biotherapy, Inc. Composition d'il2 activable et procédés d'utilisation
CN116194480A (zh) * 2020-08-13 2023-05-30 百时美施贵宝公司 将il-2重定向到目的靶细胞的方法
TW202317623A (zh) * 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
US20250032582A1 (en) * 2022-02-11 2025-01-30 Mural Oncology, Inc. Compositions and methods for cancer immunotherapy
WO2023159135A2 (fr) * 2022-02-16 2023-08-24 University Of Miami Protéines de fusion il-2 et tl1a et leurs procédés d'utilisation
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
JP2026508209A (ja) * 2023-02-22 2026-03-10 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 抗ｉｌ２ｒａ抗体及びその使用
WO2025207491A1 (fr) * 2024-03-25 2025-10-02 Mural Oncology, Inc. Compositions et méthodes pour immunothérapie anticancéreuse

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
AU717779C (en) 1994-12-28 2002-12-05 University Of Kentucky Recombinant anti-idiotype antibody 3H1 sequences relating to human carcinoembryonic antigen
US6967092B1 (en) * 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
WO2003029475A1 (fr) * 2001-09-28 2003-04-10 Dnavec Research Inc. Vecteur viral infectant une cellule de mammifere, codant pour la $g(b)2m liee a un epitope
EP1723251A4 (fr) 2004-03-05 2008-04-23 Novartis Vaccines & Diagnostic Systeme de tests in vitro permettant de predire la tolerabilite d'agents therapeutiques chez des patients
PL1899364T5 (pl) * 2005-05-17 2024-12-09 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
CN101255197B (zh) 2008-03-28 2012-01-25 浙江海正药业股份有限公司 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
EP2553101A4 (fr) * 2010-04-02 2013-09-04 Univ Rochester Cytokines activées par des protéases
WO2012088383A2 (fr) 2010-12-23 2012-06-28 Genentech, Inc. Interactions pilr alpha et procédés visant à les modifier
DK2859015T3 (en) * 2012-06-08 2018-06-18 Alkermes Inc LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS
US20140044675A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2014100913A1 (fr) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Amélioration de la demi-vie d'un polypeptide thérapeutique par fusion avec une protéine d'échafaudage trimère via un espaceur
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Also Published As

Publication number Publication date
EA201790063A1 (ru) 2017-06-30
SG11201700706WA (en) 2017-02-27
FI3177307T3 (fi) 2024-10-04
JP6723982B2 (ja) 2020-07-15
HRP20241258T1 (hr) 2024-12-06
EA035956B1 (ru) 2020-09-04
CA2957273A1 (fr) 2016-02-11
MA40094B1 (fr) 2022-05-31
JP2021000084A (ja) 2021-01-07
LT3177307T (lt) 2024-08-12
KR102653758B1 (ko) 2024-04-04
NZ766851A (en) 2024-07-26
SA517380842B1 (ar) 2021-12-26
NZ728042A (en) 2024-07-26
EA202091342A2 (ru) 2020-11-30
RS65930B1 (sr) 2024-10-31
AU2020203352A1 (en) 2020-07-02
BR112017001940A2 (pt) 2017-11-28
EP4438621A2 (fr) 2024-10-02
MY180831A (en) 2020-12-10
US20170233448A1 (en) 2017-08-17
CN107074967B (zh) 2021-06-08
ZA201700245B (en) 2024-06-26
US12084483B2 (en) 2024-09-10
TN2017000020A1 (en) 2018-07-04
IL250007B (en) 2020-07-30
PH12017500042A1 (en) 2017-05-22
EP4438621A3 (fr) 2024-12-18
EP3177307B1 (fr) 2024-07-17
IL275944A (en) 2020-08-31
SG10201913695PA (en) 2020-03-30
WO2016022671A1 (fr) 2016-02-11
MX388977B (es) 2025-03-20
EP3177307A1 (fr) 2017-06-14
AU2015301071A1 (en) 2017-02-02
AU2020203352B2 (en) 2022-03-10
CN107074967A (zh) 2017-08-18
IL275944B (en) 2022-02-01
AU2022204034A1 (en) 2022-07-14
MA40094A1 (fr) 2021-09-30
DK3177307T3 (da) 2024-10-07
US20230079120A1 (en) 2023-03-16
SMT202400414T1 (it) 2024-11-15
US20250163118A1 (en) 2025-05-22
HUE068478T2 (hu) 2025-01-28
AU2015301071C1 (en) 2020-07-02
PE20170503A1 (es) 2017-05-11
CO2017002166A2 (es) 2017-05-19
EA202091342A3 (ru) 2020-12-30
AU2015301071B2 (en) 2020-03-05
CA2957273C (fr) 2023-03-14
ES2986097T3 (es) 2024-11-08
MA40721A (fr) 2017-06-13
CN113912737A (zh) 2022-01-11
MX2017001062A (es) 2017-07-14
SI3177307T1 (sl) 2024-09-30
JP7272663B2 (ja) 2023-05-12
JP2017523789A (ja) 2017-08-24
KR20170030646A (ko) 2017-03-17
IL250007A0 (en) 2017-03-30
CL2017000284A1 (es) 2017-11-17
JP2023099045A (ja) 2023-07-11
PT3177307T (pt) 2024-09-13

Similar Documents

Publication Publication Date Title
MA40094A1 (fr) Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
SA521422459B1 (ar) مثبطات غير قابلة للانعكاس لتفاعل المينين - mll
CY1123783T1 (el) Antiσωμαta enanti-b7-h3 και συζευγματα αντισωματος φαρμακου
MY202480A (en) Fusion protein containing tgf- receptor and medicinal uses thereof
MX2021008144A (es) Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.
MX386014B (es) Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma.
PE20181338A1 (es) Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden
BR112022001575A2 (pt) Formulações de anticorpos anti-pvrig e usos dos mesmos
MX2021003475A (es) Metodos de purificacion de proteinas.
EA201991207A1 (ru) Новые агонисты tnfr и их применение
MX2021000083A (es) Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
EP4223784A3 (fr) Compositions et procédés pour moduler une réponse immunitaire à médiation par des lymphocytes t
MX2016016063A (es) Proteinas de fusion de citocina-1 inhibidora de macrofagos (mic-1) y usos de las mismas.
MA45941A (fr) Anticorps de membres de la superfamille anti-tnfr modifiés par fc ayant une activité agoniste améliorée et leurs procédés d'utilisation
MA39096B1 (fr) Anticorps spécifiques à fcrn
EP3478301A4 (fr) Modification de parasites pour l'administration de protéines dans le système nerveux central.
CR20220322A (es) Formulaciones de anticuerpos anti-pd-l1
MX2021002208A (es) Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
BR112021014566A2 (pt) Moduladores de gpr35
PH12020551582A1 (en) Lfa3 variants and compositions and uses thereof
CL2021000999A1 (es) (divisional de solicitud 1815-2016) combinaciones que comprenden agonistas ortostéricos o moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso.
MA55287A (fr) Agents de liaison au potassium destinés à être utilisés chez des patients sous hémodialyse